Bioinformatician

Centre for Oncology and Immunology Limited

Hong Kong SAR

On-site Full Time 3 year or below Entry level

Applications are invited for appointment as Bioinformatician (Ref.: H03/2023/05) , to commence as soon as possible, on a fixed-term basis, with the possibility of renewal subject to satisfactory performance and mutual agreement.

Applicants are expected to perform the following duties:

• Co-ordinating research projects and developing research methods;
• Processing clinical and investigative data;
• Statistical analysis;
• Working independently on statistical modelling, algorithm development, and high-throughput sequencing data analysis;
• Performing other tasks as assigned.

Applicants should possess a Master or PhD degree in Bioinformatics, Biostatistics, or related disciplines, preferably with relevant research experience in Cancer Biology, Bioinformatics, Immuno-oncology, or Single Cell Technology (scRNAseq, sc-ATACseq, 10X genomics & illumina platform). Work experiences at local universities and research core facilities will be an asset.

Strong working knowledge of programming languages (Python, Perl, C++, or R), basic data network configuration, and statistical software packages is a must. A good publication record showing competence in bioinformatics would be an advantage.

The applicants should have a good command of written and spoken English and strong communication skills, be a team player, self-motivated, organized, detail-minded, hardworking, willing to learn new techniques, and able to work well in a multidisciplinary team.

The appointee shall work in Hong Kong Science and Technology Park.

Overseas graduates are welcome to apply; the qualification awarding institution should be among the top 100 institutions for STEM-related subjects in QS/Shanghai Jiao Tong Uni/Times Higher Education/U.S. News world university rankings.

A highly competitive salary commensurate with qualifications and experience will be offered, in addition to annual leave and medical benefits.

Applicants should submit their up-to-date C.V. and research publication list, quoting the job reference number, with information of current/expected remuneration and availability, to

Review of applications will commence as soon as possible or until the posts are filled, whichever is earlier.

The personal data provided in your application process will be used for recruitment and other employment-related purposes. The personal data may be transferred and disclosed to, and used by HKU Innovation Holdings Limited and The University of Hong Kong for the above purposes.

We are an equal opportunities employer and welcome applications from all qualified candidates.

Entry level

10/01/2025

H03/2023/05

Laboratory

Life Science

Research & Development (R&D)

Digestive malignancies, including gastric, colorectal, liver, and esophageal cancers as well as leukemias and lymphomas, are major health burdens in Asian countries. Today, gastrointestinal and liver cancers are becoming more common across Asia due to population aging, growth, and a rise in risk factors ranging from oncogenic pathogen infections to increased smoking and obesity. Under the auspices of the InnoHK initiative, the Centre for Oncology and Immunology aims to harness the power of biotechnology to develop innovative therapies to combat these hard-to-treat malignancies and bring hope to millions of cancer patients around the world.

The Centre for Oncology and Immunology is co-led by Professor Tak MAK and Professor Suet-yi LEUNG of the Department of Pathology at HKUMed in discovering novel therapies in cancer treatment. The Centre’s research team comprises globally renowned researchers who bring with them a wealth of complementary expertise and experience in oncology research, technology adoption, and commercialization. Individually, their research programs have led to major breakthroughs, including the devising of immunotherapy and checkpoint inhibition strategies that have been adopted as anti-cancer treatments, the establishment of next-generation organoid-based cell models for precision oncology, and the development of a diagnostic test for Lynch Syndrome (hereditary colon cancer).

The Centre will employ novel functional screens as well as genomic and proteomic techniques to identify novel “druggable” cancer targets. Leveraging the translational and clinical trial expertise of its lead scientists, the Centre will establish a number of advanced technical platforms to facilitate its overall goal of bringing candidate drugs and novel immunotherapy approaches into clinics. Success in this venture will address pressing unmet medical needs and establish Hong Kong as a leading hub of innovative anti-cancer and immuno-oncology drug development.